EP0667870A4 - COMPOSITIONS ET PROCEDES PERMETTANT DE MODIFIER L'ACTIVITE REGULATRICE DU FACTEUR DE CROISSANCE TISSULAIRE--g(b) (TGF--g(b)). - Google Patents

COMPOSITIONS ET PROCEDES PERMETTANT DE MODIFIER L'ACTIVITE REGULATRICE DU FACTEUR DE CROISSANCE TISSULAIRE--g(b) (TGF--g(b)).

Info

Publication number
EP0667870A4
EP0667870A4 EP94900408A EP94900408A EP0667870A4 EP 0667870 A4 EP0667870 A4 EP 0667870A4 EP 94900408 A EP94900408 A EP 94900408A EP 94900408 A EP94900408 A EP 94900408A EP 0667870 A4 EP0667870 A4 EP 0667870A4
Authority
EP
European Patent Office
Prior art keywords
tgf
modifying
compositions
methods
regulatory activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94900408A
Other languages
German (de)
English (en)
Other versions
EP0667870A1 (fr
Inventor
Michelle Letarte
Joan Massague
Carmelo Bernabeu
Sela Cheifetz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Consejo Superior de Investigaciones Cientificas CSIC
Memorial Sloan Kettering Cancer Center
Original Assignee
HSC Research and Development LP
Consejo Superior de Investigaciones Cientificas CSIC
Sloan Kettering Institute for Cancer Research
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/968,953 external-priority patent/US5830847A/en
Application filed by HSC Research and Development LP, Consejo Superior de Investigaciones Cientificas CSIC, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center filed Critical HSC Research and Development LP
Publication of EP0667870A1 publication Critical patent/EP0667870A1/fr
Publication of EP0667870A4 publication Critical patent/EP0667870A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP94900408A 1992-10-30 1993-10-26 COMPOSITIONS ET PROCEDES PERMETTANT DE MODIFIER L'ACTIVITE REGULATRICE DU FACTEUR DE CROISSANCE TISSULAIRE--g(b) (TGF--g(b)). Withdrawn EP0667870A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96895492A 1992-10-30 1992-10-30
US968953 1992-10-30
US07/968,953 US5830847A (en) 1992-10-30 1992-10-30 Soluble TGF-β-binding endoglin polypeptides and homodimers
US968954 1992-10-30
PCT/US1993/010307 WO1994010187A1 (fr) 1992-10-30 1993-10-26 COMPOSITIONS ET PROCEDES PERMETTANT DE MODIFIER L'ACTIVITE REGULATRICE DU FACTEUR DE CROISSANCE TISSULAIRE-β (TGF-β)

Publications (2)

Publication Number Publication Date
EP0667870A1 EP0667870A1 (fr) 1995-08-23
EP0667870A4 true EP0667870A4 (fr) 1998-04-01

Family

ID=27130519

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94900408A Withdrawn EP0667870A4 (fr) 1992-10-30 1993-10-26 COMPOSITIONS ET PROCEDES PERMETTANT DE MODIFIER L'ACTIVITE REGULATRICE DU FACTEUR DE CROISSANCE TISSULAIRE--g(b) (TGF--g(b)).

Country Status (5)

Country Link
EP (1) EP0667870A4 (fr)
JP (1) JPH08504577A (fr)
AU (1) AU5541094A (fr)
CA (1) CA2147754A1 (fr)
WO (1) WO1994010187A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU688409B2 (en) * 1993-11-19 1998-03-12 University Of Sydney, The A method for preventing or controlling cataract
JPH09505057A (ja) * 1993-11-19 1997-05-20 ザ・ユニバーシティ・オブ・シドニー 白内障を予防または制御するための方法
CA2156767A1 (fr) * 1994-08-25 1996-02-26 Kenichi Matsunaga Agent liant pour facteur de croissance
WO2002067978A1 (fr) * 2001-02-23 2002-09-06 Wyeth Utilisation des protéines bmp pour potentialiser la chondrogenèse par les cellules cd105+ tirées de la moelle osseuse humaine
JP5602365B2 (ja) 2005-10-25 2014-10-08 ザ・ジョンズ・ホプキンス・ユニバーシティ マルファン症候群及び関連疾患を治療するための方法及び組成物。
EP1998810A4 (fr) 2006-03-13 2009-09-02 Univ Johns Hopkins Augmentation de la thromborésistance endothéliale
PL2083863T3 (pl) 2006-10-03 2015-08-31 Genzyme Corp Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
RU2559532C2 (ru) 2006-11-02 2015-08-10 Акселерон Фарма, Инк. Антагонисты рецептора и лигандов alk1 и их применение
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
CA2723449C (fr) 2008-05-02 2020-01-21 Acceleron Pharma Inc. Methodes et compositions fondees sur des antagonistes alk1 servant a la modulation d'angiogenese et de couverture pericyte
WO2012090997A1 (fr) 2010-12-27 2012-07-05 京都府公立大学法人 CELLULES SPi ET LEUR PROCÉDÉ DE PRODUCTION
CN108341863A (zh) * 2011-04-20 2018-07-31 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
EP2737083A1 (fr) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Méthodes de diagnostic et de traitement du syndrome de myhre
CA2853484C (fr) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine dans le traitement d'une maladie fibreuse
EP2799537B1 (fr) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalisation d'une culture de cellules endothéliales de la cornée
JP6546587B2 (ja) 2013-10-25 2019-07-17 アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． 線維性疾患を処置するためのエンドグリンポリペプチド
EP3804760A1 (fr) 2013-10-31 2021-04-14 Kyoto Prefectural Public University Corporation Médicament thérapeutique pour des maladies liées à la mort cellulaire du réticulum endoplasmique dans l'endothélium cornéen
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9410187A1 *

Also Published As

Publication number Publication date
CA2147754A1 (fr) 1994-05-11
JPH08504577A (ja) 1996-05-21
WO1994010187A1 (fr) 1994-05-11
EP0667870A1 (fr) 1995-08-23
AU5541094A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
EP0576178A3 (fr) Procédé pour maintenir les relations entre des éléments.
ZA939656B (en) Microvicidal compositions.
EP0667870A4 (fr) COMPOSITIONS ET PROCEDES PERMETTANT DE MODIFIER L'ACTIVITE REGULATRICE DU FACTEUR DE CROISSANCE TISSULAIRE--g(b) (TGF--g(b)).
EP0650370A4 (fr) Procedes et compositions permettant de cibler des tissus specifiques.
TW351991U (en) Diaper
EP0597463A3 (en) Thermotherapiesonde.
EP0598412A3 (fr) Composition pour la protection de la peau.
EP0580285A3 (fr) Auto-réenclencheurs.
EP0611302A4 (fr) Procedes et compositions servant a traiter des reactions allergiques.
EP0652749A4 (fr) PROCEDE ET COMPOSITIONS UTILISES POUR INHIBER L'ACTIVITE DE LA 5-g(a)-REDUCTASE.
ZA939369B (en) Method of milling.
EP0671929A4 (fr) Compositions.
GB2271059B (en) Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives.
ZA919900B (en) Phosphate esters and compositions containing them.
EP0567088A3 (fr) Procédé de préparation d'un inhibiteur d'amylase.
EP0572808A3 (fr) Système de régulation antiblocage.
EP0656791A4 (fr) Compositions et methodes therapeutiques a base de 2,7,9-tricarboxy-pyrroloquinoleine (pqq).
AU5602494A (en) Catalytic aromatic saturation in the presence of halide
HU9303342D0 (en) 2-alkoxy-2-imidazoline-5-one derivatives and fungicidal compositions containing them
GB9201761D0 (en) Active cancellation
GR3026571T3 (en) Preparation of 2-H-heptafluoropropane.
ZA933151B (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds.
ZA93886B (en) Bleaching regulator compositions and bleaching processes using them.
GR3024654T3 (en) Benzofuranone and benzodifurantrione derivatives and process for the preparation of benzodifuranones.
AU3737289A (en) Agent for treating pancreatitis or the like

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

RHK1 Main classification (correction)

Ipc: C07H 21/02

RHK1 Main classification (correction)

Ipc: C12N 15/12

A4 Supplementary search report drawn up and despatched

Effective date: 19980216

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK FR GB IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990503